Rapport Therapeutics Inc....
13.44
0.75 (5.91%)
At close: Jan 15, 2025, 12:25 PM

Cashflow (Annual)

Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
Year FY23 FY22
Net Income -34.79M -10.65M
Depreciation & Amortization 112.00K 15.00K
Stock-Based Compensation 3.52M n/a
Other Working Capital 1.80M 1.49M
Other Non-Cash Items 1.32M 5.94M
Deferred Income Tax n/a n/a
Change in Working Capital 2.65M 1.49M
Operating Cash Flow -27.18M -3.24M
Capital Expenditures -1.64M -284.00K
Acquisitions n/a n/a
Purchase of Investments -77.22M n/a
Sales Maturities Of Investments n/a n/a
Other Investing Acitivies n/a -5.00M
Investing Cash Flow -78.86M -5.28M
Debt Repayment n/a 7.90M
Common Stock Repurchased -4.00K n/a
Dividend Paid n/a n/a
Other Financial Acitivies 145.09M n/a
Financial Cash Flow 145.14M 39.69M
Net Cash Flow 39.09M 31.16M
Free Cash Flow -28.82M -3.53M